Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy
FASEB BioAdvances · 2023-05 · 5 (5) · 211-220
DOI: 10.1096/fba.2022-00141 ↗Kurz gefasst
Fachartikel in der Zeitschrift FASEB BioAdvances, online erschienen am 13.03.2023. Verfasst von Amiee Dowdell und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing University of Newcastle Callaghan New South Wales Australia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Glioblastoma (GBM) is the most frequent and deadly primary brain tumor in adults. Temozolomide (TMZ) is the standard systemic therapy in GBM but has limited and restricted efficacy. Better treatments are urgently needed. The role of endoplasmic reticulum stress (ER stress) is increasingly described in GBM pathophysiology. A key molecular mediator of ER stress, the spliced form of the transcription factor x‐box binding protein 1 (XBP1s) may constitute a novel therapeutic target; here we report XBP1s expression and biological activity in GBM. Tumor samples from patients with GBM ( n = 85) and low‐grade glioma ( n = 20) were analyzed by immunohistochemistry for XBP1s with digital quantification. XBP1s expression was significantly increased in GBM compared to low‐grade gliomas. XBP1s mRNA showed upregulation by qPCR analysis in a panel of patient‐derived GBM cell lines. Inhibition of XBP1 splicing using the small molecular inhibitor MKC‐3946 significantly reduced GBM cell viability and potentiated the effect of TMZ in GBM cells, particularly in those with methylated O 6 ‐methylguanine‐DNA methyl transferase gene promoter. GBM cells resistant to TMZ were also responsive to MKC‐3946 and the long‐term inhibitory effect of MKC‐3946 was confirmed by colony formation assay. In conclusion, this data reveals that XBP1s is overexpressed in GBM and contributes to cancer cell growth. XBP1s warrants further investigation as a clinical biomarker and therapeutic target in GBM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing University of Newcastle Callaghan New South Wales Australia.
- Hunter Medical Research Institute University of Newcastle New Lambton Heights New South Wales Australia.
- School of Medicine and Public Health, College of Health, Medicine and Wellbeing University of Newcastle Callaghan New South Wales Australia.
- Department of Medical Oncology Calvary Mater hospital Newcastle New South Wales Australia.
- Hunter Cancer Biobank: NSW Regional Biospecimen and Research Services University of Newcastle Callaghan New South Wales Australia.
ORCID-Profile: Sam Faulkner
Zitieren
APA
Dowdell, A., Marsland, M., Faulkner, S., Gedye, C., Lynam, J., Griffin, C. P., Marsland, J., Jiang, C. C., & Hondermarck, H. (2023). Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy. FASEB BioAdvances, 5(5), 211-220. https://doi.org/10.1096/fba.2022-00141
Vancouver
Dowdell A, Marsland M, Faulkner S, Gedye C, Lynam J, Griffin CP, et al. Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy. FASEB BioAdvances. 2023;5(5):211-220. doi:10.1096/fba.2022-00141
BibTeX
@article{Dowdell2023,
author = {Dowdell, Amiee and Marsland, Mark and Faulkner, Sam and Gedye, Craig and Lynam, James and Griffin, Cassandra P and Marsland, Joanne and Jiang, Chen Chen and Hondermarck, Hubert},
title = {Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy},
journal = {FASEB BioAdvances},
year = {2023},
volume = {5},
number = {5},
pages = {211--220},
doi = {10.1096/fba.2022-00141}
}
EUVIMED